Alpha Sense BI

MARCH 13, 2024

billion acquisition of Carmot Therapeutics, a clinical-stage biotechnology company with three GLP-1 assets in clinical production, including its CT-388 lead GLP-1 asset, in the hopes of gaining a competitive footing among Novo Nordisk and Eli Lilly’s products currently on the market (Ozempic, Wegovy, and Mounjaro, respectively).

Pharmaceutical 59

Pharmaceutical Hospitals Due Diligence Biotech 59

Alpha Sense BI

SEPTEMBER 15, 2023

Additionally, healthcare companies are keen on expanding their valuation and capabilities through M&A with medtech companies to get the competitive edge. M&A Activity is at a Decline Across Global Markets Though the medtech dealmaking space remained quiet in 2022 , analysts predicted a resurgence in 2023. Valued at $456.9

Hospitals 105

Hospitals Due Diligence Innovation Globalization 105

Alpha Sense BI

OCTOBER 6, 2023

While new devices are emerging at a rapid clip, the market is far from saturated. Opportunities abound for innovative medical device companies that can create a wearable or biometric device that provides value to consumers, while easing pressure on hospitals and healthcare facilities.

Hospitals 59

Hospitals Startups Due Diligence Innovation 59

Alpha Sense BI

APRIL 12, 2024

AlphaSense, a leading artificial intelligence (AI)-based market intelligence platform , offers proprietary Expert Insights through its extensive expert transcript library and Expert Call Services. You think, ‘I have competitively a better methodology, a better framework, and you think the world will go on it.’

Primary Research 52

Primary Research Advantage Advantage Research 52